Table 2.
Results of major Phase III studies using combination therapies in first-line therapy for metastatic gastric cancer
| n | Regimen | RR (%) | TTF | P value | Median PFS | P value | Median OS | P value | |
|---|---|---|---|---|---|---|---|---|---|
| Waters et al18 | 130/126 | FAMTX/ECF | 21/46 | – | – | – | – | 6.1/8.7 | 0.0005 |
| Vanhoefer et al17 | 134/132/133 | CF/ELF/FAMTX | 20/9/12 | – | – | 4.1/3.3/3.3 | NS | 7.2/7.2.6.9 | NS |
| Van Cutsem et al20 | 224/221 | CF/DCF | 25/37 | – | – | 3.7/5.6 | <0.001 | 8.6/9.2 | 0.02 |
| Cunningham et al27 | 263/245/250/244 | ECF/EOF/ECX/EOX | 41/42/46/48 | – | – | 6.2/6.5/6.7/7 | NS | 9.9/9.3/9.9/11.2 | 0.02 |
| Dank et al30 | 172/165 | IF/CF | 31.8/25.8 | 4/3.4 | 0.0018 | 7.4/7.6 | NS | 9/8.7 | NS |
| Guimbaud et al31 | 174/175 | ECX/ FOLFIRI | 4/5 | 0.008 | 5.3/5.75 | – | 9.5/9.7 | NS | |
| Boku et al32 | 234/235/234 | 5-FU/CP/S-1 | 9/38/28 | – | – | – | – | 10.8/12.3/11.4 | NS |
| Kang et al34 | 160/156 | XP/FP | 46/32 | – | – | 5.6/5 | NS | 10.5/9.3 | NS |
| Koizumi et al35 | 148/150 | CS-1/S-1 | 54/31 | – | – | 6/4 | <0.0001 | 13/11 | 0.04 |
| Ajani et al36 | 527/526 | CS-1/CF | 29.1/31.9 | – | – | 4.8/5.5 | NS | 8.6/7.9 | NS |
Abbreviations: n, number of patients; NS, not significant; RR, response rate; TTF, time to treatment failure; PFS, progression free survival; OS, overall survival; F, fluorouracil; 5-FU, infusional 5-fluorouracil; A, adriamycin; MTX, methotrexate; E, epirubicin; C, cisplatin; L, leucovorin; D, docetaxel; O, oxaliplatin; X, capecitabine; I or IRI, irinotecan.